TOLERANZIA AB
Toleranzia develops drugs that utilize the immune system's own intrinsic power to treat autoimmune orphan diseases. The drugs, which target the disease cause, can cure or greatly alleviate the disease and not just reduce the symptoms that current treatments do. The company's drug candidate, TOL2, is developed for the autoimmune nerve and muscle disease myasthenia gravis.
TOLERANZIA AB
Industry:
Business Development Pharmaceutical
Founded:
2011-01-01
Address:
Gothenburg, Vastra Gotaland, Sweden
Country:
Sweden
Website Url:
http://www.toleranzia.se
Total Employee:
1+
Status:
Active
Contact:
+46-763-19 98 98
Email Addresses:
[email protected]
Total Funding:
71.43 K EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Chaperone Therapeutics
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
Current Employees Featured
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Toleranzia AB
Official Site Inspections
http://www.toleranzia.se
- Host name: uke.oderland.com
- IP address: 91.201.61.217
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
